RHÖN-KLINIKUM AG : Good timing to anticipate taking profits
Entry price | Target | Stop-loss | Potential |
---|
€28.18 |
€26.75 |
€28.65 |
+5.07% |
---|
Rhoen Klinikum AG shares have recently benefitted from renewed interest and are reverting to attractive levels at which sales could be contemplated.
Strengths● The company is in a robust financial situation considering its net cash and margin position.
● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 25.4 EUR
Weaknesses● The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
● According to forecast, a sluggish sales growth is expected for the next fiscal years.
● The company's earnings releases usually do not meet expectations.
● With an expected P/E ratio at 58.05 and 36.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
● For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
● For the past year, analysts have significantly revised downwards their profit estimates.
● Most analysts recommend that the stock should be sold or reduced.
● The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.